News | March 06, 2009

Minority Patients Less Likely to Receive Treatment for Advanced Heart Failure

March 6, 2009 – New research published in the March edition of the HeartRhythm Journal reveals that black and Hispanic patients who were eligible for cardiac resynchronization therapy with defibrillator (CRT-D) were less likely to receive therapy than eligible white patients.

The study also found that both minority groups were more likely to meet established criteria and white patients were more likely to receive CRT-D outside of published guidelines. The new study is the first of its kind to examine and compare Hispanic, white and black patients within a national study population.

The national study examined 108,341 participants in more than 1,000 hospitals enrolled in the National Cardiovascular Data Registry (NCDR) from January 2005 through April 2007. The NCDR ICD Registry, developed in collaboration with the American College of Cardiology and the Heart Rhythm Society, was examined for racial and ethnic disparities in CRT-D implantation.

Lead author Steven A. Farmer, M.D., Cardiovascular Division at the Hospital of the University of Pennsylvania in Philadelphia, reviewed the data and the number of patients who met established guidelines. Of the 108,341 registry participants:

- 22,205 patients met guidelines to receive an ICD or CRT-D
- 27,165 patients received CRT-D therapy, more than the actual number of people who were eligible.

Results conclude that CRT-eligible black and Hispanic patients were less likely to receive CRT-D than were white patients. A substantial proportion of patients received CRT-D outside of published guidelines, although black and Hispanic patients were more likely to meet all eligibility criteria.

“These results reinforce a number of questions about how race and ethnicity can impact who receives advanced treatment for heart failure,” Dr. Farmer stated. “It is very surprising that there are a significant number of ICD patients who meet the required criteria for CRT-D and are not receiving the therapy, while many patients who receive the treatment fail to meet those same guidelines.”

For more information: www.heartrhythmjournal.com.

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init